Advanced searches left 3/3

Placebo - DOAJ

Summarized by Plex Scholar
Last Updated: 26 September 2022

* If you want to update the article please login/register

Extraoral low-level laser therapy can decrease pain but not edema and trismus after surgical extraction of impacted mandibular third molars: a randomized, placebo-controlled clinical trial

Following the surgical removal of impacted mandibular third molars, this review was conducted to determine the effect of an extraoral 940 nm low-level diode laser on pain, edema, and trismus. Materials and methods This split-mouth, randomized, placebo-controlled clinical trial evaluated 25 patients with bilaterally affected third molars. At three points in the master muscle in contact mode immediately after surgical removal of a third molar, the laser quadrant received 940 nm diode laser irradiation at three points. The third molar in the placebo quadrant was extracted after 2 weeks by the same surgeon using the same general method. The distance between the tragus and chin point was determined before and immediately after surgery, and after 2 and 7 days, in order to determine edema. The mean pain score in the first seven days of the laser program was significantly lower in the first 7 days.

Source link: https://doi.org/10.1186/s12903-022-02461-2


A randomised placebo-controlled trial of the effectiveness of early metformin in addition to usual care in the reduction of gestational diabetes mellitus effects (EMERGE): study protocol

Background Paper Pregnancy Pregnancies affected by gestational diabetes mellitus are at an elevated risk of adverse maternal and foetal outcomes. In those with persistent hyperglycaemia, initial medical nutritional therapy, exercise, and pharmacotherapy are among the current GDM drugs. Metformin is safe in select groups of women with GDM, but not in many guidelines due to a lack of long-term evidence on efficacy. The EMERGE trial will determine the effects of metformin early in GDM's use. Discussion The EMERGE trial will determine the effectiveness and safety of metformin use in GDM earlier and often.

Source link: https://doi.org/10.1186/s13063-022-06694-y


Inhaled aviptadil for the possible treatment of COVID-19 in patients at high risk for ARDS: study protocol for a randomized, placebo-controlled, and multicenter trial

Abstract Background Despite the rapid development of new therapeutic agents in the administration of COVID-19 and large-scale vaccination programs as the result of the SARS-CoV-2 pandemic in early 2020, severe disease courses remain a threat, particularly to patients with risk factors. COVID-19's acute respiratory distress syndrome is one of the most common respiratory disorders that cause respiratory problems such as acute respiratory distress syndrome. Aviptadil, a synthetic form of human vainoactive intestinal peptide, may be helpful to COVID-19 patients at risk of ARDs due to its ability to influence the regulation of exaggerated pro-inflammatory proteins and orchestrate lung homeostasis. When applied intravenously, Aviptadil has been shown to greatly increase the prognosis of ARDs in COVID-19. Inhaled aviptadil in patients hospitalized for COVID-19 are at a high risk of experiencing ARDs. The overall aim of this study is to determine the efficacy and safety of inhaled aviptadil in patients hospitalized for COVID-19. Methods In five European public hospitals, this multicenter, placebo-controlled, double-blinded, controlled trial of 132 adult patients hospitalized for COVID-19 and at risk of ARDS is being conducted. According to the World Health Organisation, the key endpoint is time from hospitalization to clinical development, which can be defined as either hospital discharge or rise of at least two points on the nine-level scale for clinical status. COVID-19 treatment options are also limited. Discussion of COVID-19 Treatment methods is still limited. Inhaled aviptadil may have the ability to prevent ARDs in COVID-19 due to its unique immunomodulating capabilities also targeting the SARS-CoV-2 pathway.

Source link: https://doi.org/10.1186/s13063-022-06723-w


Follow-up study of infants recruited to the randomised, placebo-controlled trial of azithromycin for the prevention of chronic lung disease of prematurity in preterm infants—study protocol for the AZTEC-FU study

When compared to placebo, the AZTEC study has recruited 799 infants born in uterine and determined whether a ten-day intravenous treatment with azithromycin increases survival without developing persistent lung disease of prematurity at 36 weeks old. In the early neonatal period, infants who received azithromycin, neurodevelopmental, and growth results will be compared between infants who received azithromycin and those who received placebo. Survivors at 36 weeks,u2019 PMA from the main Azithromycin Therapy for Chronic Lung Disease of Prematurity study with parental permission will continue to be monitored up to discharge from the neonatal unit and to 2 years of corrected age. Discussion The AZTEC-FU study will investigate mortality and other important neonatal morbidities such as respiratory, neurodevelopmental, and growth outcomes.

Source link: https://doi.org/10.1186/s13063-022-06730-x


Acipimox in Mitochondrial Myopathy (AIMM): study protocol for a randomised, double-blinded, placebo-controlled, adaptive design trial of the efficacy of acipimox in adult patients with mitochondrial myopathy

Mitochondrial disease is a heterogenous group of rare, complex neurometabolic disorders. Despite individual's uniqueness, mitochondrial diseases are the most common cause of inherited metabolic disorders in the United Kingdom; they affect 1 out of every 4300 individuals, up to 15,000 adults in the United Kingdom, affecting 1 in every 15,000 adults. Mitochondrial disease has a multisystem and local organ involvement, most commonly impacting those organs that require high energy requirements, such as skeletal muscle. Patients with mitochondrial disease have fatigue, muscle weakness, and exercise intolerance, which can be both debilitating and debilitating. Aim To study the effectiveness of 12-week acipimox therapy on skeletal muscle adenosine triphosphate levels in patients with mitochondrial disease and myopathy. Methods anomox is a single-centre, double blind, placebo-controlled, adaptive trial evaluating the safety of the acipimox administration in mitochondrial myopathy patients with mitochondrial myopathy in patients with mitochondrial myopathy. Eligible patients will be provided with the trial investigational medical drug, whether acipimox or matched placebo. In order to safeguard the treatment assignment's blindness, participants will also be provided low dose aspirin as a non-investigational medical drug. Between baseline and 12 weeks, the key results of the change in ATP content in skeletal muscle, perceived exhaustion, disease burden, ankle balance, and walking will be determined. Discussion The AIMM trial will determine whether acipimox will influence muscle ATP levels and whether it can be repurposed as a new therapy for mitochondrial disease with myopathy.

Source link: https://doi.org/10.1186/s13063-022-06544-x


Corosolic acid improves glucose and insulin responses in middle-aged men with impaired fasting glucose: A randomized, double-blinded, placebo-controlled crossover trial

The incremental area under the curve of plasma glucose before the OGTT was significantly smaller in the CA condition than in the placebo group. The serum insulin and C-peptide concentrations in the AUC and iAUC were also significantly lower in the CA environment, with liver insulin sensitivity values being significantly lower in the CA condition.

Source link: https://doi.org/10.1016/j.jff.2022.105256


Clinical Investigation of French Maritime Pine Bark Extract on Attention-Deficit Hyperactivity Disorder as compared to Methylphenidate and Placebo: Part 2: Oxidative Stress and Immunological Modulation

As compared to methylphenidate and placebo, we wanted to determine the effect of French Maritime Pine Bark Extract on immune, oxidative stress, and neurochemical biomarkers in paediatric Attention-Deficit Hyperactivity Disorder. If u2265 30 kg PBE, 40 mg/day, or 20 mg/day if 30 kg or 40 mg/day, or 20 mg/day if 30 kg or 40 mg/day, if 30 kilograms or 30 mg/day, if 30 kg or 40 mg/day, or 20 mg/day if 30 kg or 30 mg/day if 30 kg or 30 mg/day, if 30 mg/day.

Source link: https://doi.org/10.1016/j.jff.2022.105247


Clinical Investigation of French Maritime Pine Bark Extract on Attention-Deficit Hyperactivity Disorder as compared to Methylphenidate and Placebo: Part 1: Efficacy in a Randomised Trial

Objectives: Determine the effect of French Maritime Pine Bark Extract on Attention Deficit Hyperactivity Disorder (TDPH) and co-morbid physical/psychiatric signs, as well as placebo and MPH, as well as measuring its tolerability. After ten weeks compared to placebo, teachers reported significant improvements in total and hyperactivity/impulsivity ADHD-RS scores by PBE and MPH.

Source link: https://doi.org/10.1016/j.jff.2022.105246


Anti-fatigue effect of OM-X, fermented plant extract with lactic acid bacteria and bifidobacteria: A randomized, placebo-controlled, double-blind, comparative study

This research seeks to clarify how the OM-X made from various species of plants fermented using lactic acid bacteria and bifidobacteria aids in anti-fatigue. To determine comprehensive antioxidative capability, comprehensive antioxidative capacity was tested on a digital analogue scale and Chalder fatigue scale. The ingestion of OM-X also increased feelings of exhaustion for healthy people with temporary exhaustion, which led to increased symptoms of exhaustion among healthy people with temporary fatigue.

Source link: https://doi.org/10.1016/j.jff.2022.105228


Effects of erinacine A-enriched Hericium erinaceus on elderly hearing-impaired patients: A double-blind, randomized, placebo-controlled clinical trial

We wanted to investigate the effects and mechanisms of Hericium erinaceus hearing degeneration. Between the two study groups' questionnaires and growth factor was used to determine the differences in the average pure tone hearing threshold of all, low, and high frequencies; speech recognition threshold; and serum concentrations of brain-derived neurotrophic factor and neurotrophic growth factor.

Source link: https://doi.org/10.1016/j.jff.2022.105220

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions